Study on the Safety and Pharmacokinetics of LM001 and Gonal-F® in Healthy Women

NCT03535103 | Unknown Phase 1

• 1 other identifier: KNJR-2018-001
• Study Type: interventional
• Target: 32
• Locations: 0 countries
• Sites: N/A

Brief Summary

Brief Summary: LM001 is a recombinant human Follicle Stimulating Hormone (r-hFSH) Injection, which is proposed for Assisted Reproductive Technology (ART). This is a randomized, open-label, two-period, two-crossover study to evaluate the safety and pharmacokinetics of recombinant human follicle stimulating hormone injection (LM001), compared with Gonal-F®, both given subcutaneously.

Conditions

Infertility, Female

Outcome Measures

Primary Outcomes (2)

• Maxmum observed serum concentration (Cmax) of LM001＆Gonal-f® in healthy Chinese female subjects.

  Maxmum observed serum concentration (Cmax) of LM001＆Gonal-f® in healthy Chinese female subjects.

  within 0.5h pre-dose, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose.

• Adjusted geometric means of area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T))for LM001＆Gonal-f® in healthy Chinese female subjects.

  Adjusted geometric means of area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T))for LM001＆Gonal-f® in healthy Chinese female subjects.

  within 0.5h pre-dose, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose.

Other Outcomes (7)

• Time of Maxmum observed serum concentration (Tmax) of LM001＆Gonal-f® in healthy Chinese female subjects.

  within 0.5h pre-dose, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose.

• Serum clearance(CL) of of LM001＆Gonal-f® in healthy Chinese female subjects.

  within 0.5h pre-dose, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose.

• Adjusted geometric means of area under the serum concentration-time curve from time zero extrapolated to infinite time(AUC(INF))for LM001＆Gonal-f® in healthy Chinese female subjects.

  within 0.5h pre-dose, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose.

Study Arms (2)

ARM A

EXPERIMENTAL

Gonal-F®

Drug: Gonal-F®

ARM B

EXPERIMENTAL

LM001

Drug: LM001

Interventions

Gonal-F® DRUG

A single Subcutaneous injection, 225IU

Also known as: Follitropin alfa

ARM A

LM001 DRUG

A single Subcutaneous injection, 225IU

Also known as: Follitropin alfa

ARM B

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Able and willing to provide written informed consent.
• Agreed to take effective contraceptive measures during and 6 months after the end of the study period.
• Age between 18 to 40 years (inclusive).
• Body weight ≥45 kg, body mass index (BMI) of ≥18 and ≤28 kg/m2,
• Regular menstruation cycle (25 to 34 days, inclusive).
• Normal findings in sex hormone examinations, including FSH, LH, prolactin (PRL), estradiol (E2), progesterone (P), testosterone (T) unless the investigator considers an abnormality to be clinically irrelevant for this study.

You may not qualify if:

• Smoke ≥5 cigarettes or the equivalent per day within 3 months prior to the study
• History of hypersensitivity to FSH, or hypersensitivity to luteinizing hormone releasing hormone agonist or something like that.
• Historic abuse of alcoholic beverages and drugs (Drink 14 units of alcohol/week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine.
• Taken any liver enzyme activity relative drug within 28 days prior to the screening.
• Take any prescription drug, OTC drug, vitamin product or herbal medicine within 14 days prior to the screening.
• Taken special diets (including pitaya, mango, grapefruit, etc.) or have strenuous exercise, or something affect the absorption, distribution, metabolism, excretion, etc. of the drug within 2 weeks prior to the study.
• Major changes in diet or exercise habits recently
• Participation in a clinical study within 3 months prior to the study.
• Acute disease or combination therapy from the screening to the beginning time of the study.
• Take any alcoholic product within 48 hours prior to the study.
• Take chocolate, any caffeine-containing or xanthine-rich food or drinks within 48 hours prior to using the drug;
• Blood donation or massive blood losing (\>450mL) within 3 months prior to the screening;
• Viral hepatitis (including hepatitis B and hepatitis C), HIV, and Treponema pallidum positive.
• History of significant diseases such as circulatory, endocrine, neurological, reproductive, digestive, and respiratory systems, hematology, immunology, psychiatry, and metabolic abnormalities, or past or current medical history that could interfere with the test results, eg subjects with or have suffered from hypothyroidism, adrenocortical insufficiency and hyperprolactinemia, polycystic ovary syndrome, and ovarian dysfunction, premature ovarian failure (POI) or primary ovarian failure, unexplained uterine bleeding, hypothalamic or pituitary tumors, ovarian, uterine or breast cancer, history of thrombosis, history of malignancy;
• Baseline of serum FSH ≥15 IU/L.

Sponsors & Collaborators

• Alphamab Jilin Co., Ltd.: lead

MeSH Terms

Conditions

Infertility, Female

Interventions

follitropin alfa

Condition Hierarchy (Ancestors)

Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Infertility

Central Study Contacts

Yanhua Ding, M.D.

CONTACT

86-0431-88782168; dingyanhua2003@126.com

lei gao, M.D.

CONTACT

398027192@qq.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 2, 2018
• First Posted: May 24, 2018
• Study Start: June 1, 2018
• Primary Completion: December 31, 2019
• Study Completion: December 31, 2019
• Last Updated: May 29, 2018

Record last verified: 2018-05